FIELD: medicine.
SUBSTANCE: inhalation aerosol formulation for treating respiratory diseases contains salmeterol or salmeterol xinafoate, fluticasone or fluticasone propionate, a propellent modifier representing perfluorodecalin, and a propellent specified in 1,1,1,2 tetrafluoroethane (HFA-134a) and/or 1,1,1,2,3,3,3-heptafluoropropane (HPA-227ea).
EFFECT: higher respirable fraction and effective pulmonary delivery of the active ingredient; the aerosol has higher stability.
1 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHALATION FORMULATION IN FORM OF AEROSOL FOR TREATING BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2012 |
|
RU2504402C1 |
| AEROSOL PREPARATION BASED ON FENOTEROL HYDROBROMIDE FOR TREATING RESPIRATORY DISEASES | 2015 |
|
RU2577289C1 |
| COMBINED AEROSOL PREPARATION FOR TREATING RESPIRATORY DISEASES | 2013 |
|
RU2536253C1 |
| AEROSOL PREPARATION OF IPRATROPIUM BROMIDE FOR TREATING RESPIRATORY DISEASES | 2013 |
|
RU2519653C1 |
| INHALATION PREPARATION FOR TREATING RESPIRATORY DISEASES CONTAINING MICRONISED SALMETEROL XINAFOATE AND MICRONISED FLUTICASONE PROPIONATE AS ACTIVE SUBSTANCES AND METHOD FOR PREPARING IT | 2012 |
|
RU2494730C1 |
| COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS | 2010 |
|
RU2586297C2 |
| METHOD AND SYSTEM FOR MDI ELECTRONIC MODEL (DOSING INHALANT DEVICE) | 2012 |
|
RU2633269C2 |
| CRYSTALLINE MICRO PARTICLES OF BETA-AGONIST, COATED WITH FATTY ACID | 2012 |
|
RU2629085C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING RPL554 IN HFA-134A FOR ADMINISTRATION BY INHALATION | 2019 |
|
RU2813959C2 |
| PHARMACEUTICAL AEROSOL COMPOSITION | 2009 |
|
RU2565438C2 |
